New Report Explores Chronic Obstructive Pulmonary Disease Treatment Market Demand Would Increase Rapidly By 2026

Press Release

Chronic Obstructive Pulmonary Disease Treatment Market – Snapshot

The global chronic obstructive pulmonary disease (COPD) treatment market is driven by increase in the number of COPD cases, rise in FDA approvals, and launch of several products in the U.S. Moreover, increase in the geriatric population and rise in expenditure on pharmaceuticals in emerging countries are the other factors contributing to the growth of the market. However, patent expiry of branded products and availability of generic equivalents and alternative treatment options are anticipated to restrain the global market.

View Report:

Based on drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and others. The combination segment has been classified into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others. The bronchodilators segment has been divided into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA). The combination segment is projected to account for major share of the market by 2026 due to increase in number of physicians prescribing combination therapy and surge in the number of drugs available for COPD treatment. The bronchodilators segment is anticipated to grow at a steady pace owing to increase in the adoption of long acting muscarinic antagonist (LAMA) drugs. In terms of distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is expected to expand at the fastest CAGR due to surge in the number of patients preferring retail pharmacies. The online pharmacies segment is likely to be driven by rise in awareness about these pharmacies among the general population.

Based on region, the global chronic obstructive pulmonary disease (COPD) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the global market in 2017. Presence of established pharmaceutical companies, increase in adoption of new drugs launched in the market, and focus on launch of new products through R&D are anticipated to drive the market in the region during the forecast period.

Request a Brochure of the Report @

The chronic obstructive pulmonary disease (COPD) treatment market in Europe is driven by increase in R&D expenditure and launch of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. received authorization from the European Commission for expanded use for once-daily Trelegy Ellipta, first single inhaler triple therapy indicated for COPD patients who were not adequately treated with dual bronchodilation.

Rise in prevalence of COPD, high environmental pollution, increase in the geriatric population, and growth of the pharmaceutical industry are anticipated to fuel the growth of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences stated that COPD is the third leading cause of death in India.

The chronic obstructive pulmonary disease (COPD) treatment market in Latin America and Middle East & Africa is expected to be driven by increase in awareness about the diagnosis and treatment of COPD, rise in the number of government initiatives to spread awareness and importance about its treatment, and surge in the number of specialty care centers for respiratory care in various countries in the Middle East. Additionally, GCC Countries such as the UAE and Saudi Arabia present significant opportunities in the market due to strengthening health care system and availability of quality care in hospitals.

Request a Sample of the Report @

Major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd., Mylan N.V., and Orion Corporation.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]


RSS news